Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 12,500 shares of the firm's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total transaction of $315,750.00. Following the completion of the sale, the president now owns 454,385 shares of the company's stock, valued at $11,477,765.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Zentalis Pharmaceuticals Price Performance
Shares of Zentalis Pharmaceuticals stock opened at $23.86 on Friday. The firm has a fifty day moving average price of $28.21 and a 200 day moving average price of $30.30. Zentalis Pharmaceuticals, Inc. has a 1 year low of $17.33 and a 1 year high of $87.19. The stock has a market cap of $1.36 billion, a PE ratio of -6.20 and a beta of 1.88.
Get
Zentalis Pharmaceuticals alerts:
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.13). As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. Cowen initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, July 12th. They issued an "outperform" rating for the company. Morgan Stanley decreased their price target on shares of Zentalis Pharmaceuticals from $95.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, August 11th. Cowen initiated coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, July 12th. They issued an "outperform" rating for the company. SVB Leerink decreased their price target on shares of Zentalis Pharmaceuticals from $67.00 to $42.00 and set an "outperform" rating for the company in a report on Wednesday, August 10th. Finally, HC Wainwright decreased their price target on shares of Zentalis Pharmaceuticals from $120.00 to $55.00 and set a "buy" rating for the company in a report on Wednesday, August 10th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $61.38.
Institutional Trading of Zentalis Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its position in Zentalis Pharmaceuticals by 14.1% during the second quarter. Federated Hermes Inc. now owns 1,085,139 shares of the company's stock valued at $30,492,000 after buying an additional 134,206 shares during the period. Amundi acquired a new stake in Zentalis Pharmaceuticals during the second quarter valued at $143,000. Legal & General Group Plc grew its position in Zentalis Pharmaceuticals by 38.1% during the second quarter. Legal & General Group Plc now owns 35,491 shares of the company's stock valued at $998,000 after buying an additional 9,791 shares during the period. Goldman Sachs Group Inc. grew its position in Zentalis Pharmaceuticals by 49.9% during the second quarter. Goldman Sachs Group Inc. now owns 397,570 shares of the company's stock valued at $11,171,000 after buying an additional 132,324 shares during the period. Finally, Woodline Partners LP grew its position in Zentalis Pharmaceuticals by 344.9% during the second quarter. Woodline Partners LP now owns 181,272 shares of the company's stock valued at $5,094,000 after buying an additional 140,524 shares during the period.
Zentalis Pharmaceuticals Company Profile
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Featured Articles
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
